Precigen To Present Late-Breaking Abstract For Pivotal Phase 2 Study Data For PRGN-2012 AdenoVerse Immunotherapy For The Treatment Of Patients With Recurrent Respiratory Papillomatosis At The 2024 ASCO Annual Meeting

Author: Benzinga Newsdesk | April 24, 2024 10:22am

Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced clinical data from the pivotal Phase 2 study of PRGN-2012 AdenoVerse immunotherapy for the treatment of patients with recurrent respiratory papillomatosis (RRP) will be presented in a late-breaking oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place from May 31 to June 4, 2024 at McCormick Place in Chicago, Illinois.

 

Abstract Title	Abstract #	Presentation Details
PRGN-2012, a novel gorilla adenovirus-based immunotherapy, provides the first treatment that leads to complete and durable responses in recurrent respiratory papillomatosis patients	LBA6015	Session Title: Rapid Oral Abstract Session – Head and Neck Cancer   Session Date and Time: June 3, 2024 8:00 AM - 9:30 AM CT

Event details are available on Precigen's website in the Events & Presentations section at investors.precigen.com/events-presentations.

Posted In: PGEN